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Abstract
The clinical management of cervical cancer in human immunodeficiency virus (HIV)
positive patients is associated with challenges mainly due to the state of their
immunity. They are managed like their HIV seronegative counterparts with surgery
or chemoradiotherapy. HIV, cervical cancer, radiotherapy and chemotherapy lower
immunity through reduction in CD4 cell counts.
A perspective on the management of HIV positive patients with cervical cancer is
hereby provided.
Available studies were reviewed and peculiar characteristics of HIV patients with
cervical cancer were examined. Strategies for managing such patients were identified.
HIV positive patients are younger and have more aggressive disease. They have more
treatment related toxicities, poorer disease control with higher rates of incomplete and
treatment delays than their HIV negative counterparts. Highly active anti-retroviral
therapy (HAART) improves treatment outcome in such patients.
HIV positive patients with cervical cancer should be commenced on HAART at
diagnosis. There should be closer monitoring of CD4 cell counts and viral load while
on oncology treatment towards early recognition of need for prophylaxes against
opportunistic infections. The dosage of the treatment modalities should also be
adjusted according to CD4 cells count status. Possible interactions between anti-
retroviral therapy (ART) with chemotherapy and radiotherapy should not be
overlooked.
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1. Introduction
Cancer of the uterine cervix is the most common gynecological malignancy and occurs
worldwide [1]. Close to eighty percent of cervical cancers occur in the developing countries [2].
Chronic persistent infections with high-risk HPV subtypes play an important role in the
carcinogenesis of cervical cancer. Human immunodeficiency virus (HIV) infection lowers
immunity and is epidemic in some developing countries especially in sub-Sahara Africa.
Cervical cancer is very common in HIV seropositive patients and is associated with an
aggressive course and poor treatment outcome [3]. The associated compromise in immunity
caused by HIV infection poses serious challenges to the clinical management of HIV positive
patients diagnosed with cervical cancer. The main modalities of managing cervical cancer are
surgery, chemotherapy and radiotherapy with most patients requiring combination therapy.
These treatment modalities lead to reduced immunity in patients which is further reduced if
one or two modalities are combined. In a patient with immunological challenges due to HIV
infection, these treatment modalities can therefore worsen the immunological competence of
the individual leading to poorer treatment tolerance, undue treatment toxicity and poor
treatment outcome. At present, HIV positive patients diagnosed with cervical cancer are being
managed using guidelines for managing HIV seronegative patients diagnosed with cervical
cancer. The outcome of treatment in HIV positive patients are worse compared with HIV
negative patients and HIV positive patients present late and are less likely to complete
oncology treatment [4]. Infection with HIV has also been noted to increase mortality among
cancer patients generally [5]. There is therefore need to consider additional therapeutic
measures applicable to cervical cancer patients who are HIV positive.
The aim of this chapter is to highlight special features associated with HIV positive patients
diagnosed with cervical cancer and provide a perspective on management strategies for these
patients. This was done through a review of the evidence from basic, epidemiological and
clinical studies which formed the basis for the recommendations for the management of HIV
positive patients diagnosed with cervical cancer.
2. Peculiarities of cervical cancer in HIV positive patients
2.1. Epidemiology of cervical cancer
Cervical cancer occurs worldwide. The incidence of cervical cancer is still high in developing
countries whereas it has decreased significantly in the developed countries over the last several
decades. Close to eighty percent of cervical cancer occur in the developing countries [2]. The
highest incidence is in sub-Sahara Africa especially in Eastern African countries [6]. Further‐
more, the mortality due to cervical cancer is about ten times higher in the developing countries
where screening and treatment modalities are neither common nor easily accessible. In
developed countries, screening is the main factor responsible for the decrease in the incidence
and mortality rates of cervical cancer.
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2.2. Risk factors for cervical cancer
The most important risk factor for the development of cervical cancer is infection with human
papilloma virus [HPV] [7]. In particular, chronic persisting infections with high-risk HPV
subtypes play an important role in the carcinogenesis of cervical cancer. The subtype mostly
implicated in cervical cancer aetiology is types 16 followed by 18. Other subtypes are also
implicated but to a lesser extent. Human Immunodeficiency Virus (HIV) infection causes low
immunity in those infected. In HIV positive patients, some less carcinogenic subtypes of HPV
have been reported to play an important role in the aetiology of cervical cancer (Table 1).
HIV seronegative
(worldwide)
HIV -1 seropositive
(single report)
HPV subtype % HPV subtype %
16 54.4 52 14.7
18 16.5 35 9.4
58 5.1 58 9.4
33 4.7 51 8.6
45 4.4 16 7.8
31 3.6 31 7.5
52 3.4 53 6.7
35 1.9 18 6.4
39 1.3
59 1.3
Table 1. Most frequent HPV types among women with invasive cervical cancer by any histology. Sources: HIV
negative: ICO HPV Information Centre (2014); HIV-1 positive: [8]. Subtypes 52 and 35 that are less carcinogenic in HIV
negative patients are more important in HIV positive patients.
2.3. Human Immunodeficiency Virus (HIV) infection
Immunodeficiency is an important cofactor for persisting infections with HPV. It increases the
virulence and aggressiveness of HPV thereby accelerating the progression to malignant
transformation of the endo-cervical epithelial cells.
Human immunodeficiency virus (HIV) lowers immunity and is epidemic in most developing
countries. Cervical cancer is very common in HIV seropositive patients and has an aggressive
course with poor treatment outcome [3]. Regions of high prevalence of cervical cancer
corresponds with regions of high prevalence of HIV infection (Figures 1& 2).
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Figure 1. Adult HIV prevalence by WHO region (WHO 2013) http://www.who.int/gho/hiv/en/. Sub-Sahara Africa has
the highest prevalence rate of 4.5% while Western Pacific and Eastern Mediterranean have the least with 0.1% preva‐
lence.
Figure 2. Estimated Cervical Cancer Incidence Worldwide in 2012 (GLOBOCAN 2012)
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2.4. HIV infection and cervical cancer
Cervical cancer is one of the malignancies commonly diagnosed in people living with HIV.
Other  commonly  associated  malignancies  in  HIV  setting  include  lymphomas,  Kaposis’
sarcoma,  anal  carcinoma and other  HPV associated malignancies  like  vulval  and penile
cancers.  Worldwide,  cervical  cancer  incidence  is  higher  among  HIV  positive  women
compared  with  HIV  negative  women.  In  a  North  American  multi-cohort  collaboration
prospective study involving 13,690 HIV positive and 12,021 HIV negative women, it was
found that HIV positive women had 7 times more incidence of cervical cancer than their
HIV negative  counterparts  [9].  In  a  study in  West  Africa  to  assess  the  relationship  be‐
tween HIV infection and cervical cancer, HIV infected women had higher rates of 22/132
(16.7%) than controls 10/120 (8.3%) (p = 0.048) [10].
Cervical cancer has been observed to occur in younger age ranges among HIV positive patients
than with HIV negative women (about 10 years younger) and the disease is also noted to have
a more aggressive course with metastasis to unusual sites like the skin and brain. Recurrences
are much earlier and frequent than in HIV negative women [11, 12]. HIV positive women are
also noted to have cervical cancer at higher CD4 counts compared with the low CD4 counts
associated with other AID associated malignancies like Kaposis‘ sarcoma and lymphomas [13].
2.5. Screening for cervical cancer
Screening for cervical cancer is an effective strategy for reducing the incidence and mortality
of cervical cancer. The availability of effective screening corresponds with reduced incidence
and mortality of the disease. It is the main reason why the incidence of cervical cancer in
developed world is less compared with developing (poor resource countries) where screening
programs are not available. The recommended schedule of screening of sexually active female
populations by The American Cancer Society is summarized in Table 2.
Population Recommended screening method
Age <21 years No screening
Age 21-29 years Cytology alone every 3 years
Age 30-65 years HPV and cytology contesting every 5 years (preferred)Cytology alone every 3 years (acceptable)
Age > 65 years No screening following adequate negative prior screening
After hysterectomy No screening
HPV vaccinated Follow age specific recommendations (same as unvaccinated women)
Table 2. Recommended screening scheme for cervical cancer (adapted from Saslow (2012) [14]
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In HIV infected individuals the progression of HPV infection to carcinogenesis is accelerated
and there is need to shorten the period of screening in women living with HIV so as to diagnose
cervical squamous epithelial changes early. In a report of long term follow up of participants
using cervical cytology, Massad and colleagues (2008) reported high grade squamous epithe‐
lial lesion of 4.4 in 1000 person-years in HIV positive patients against 1.3 in 1000-person years
among HIV negative women. At ten years observation period, the cumulative risk of abnormal
cytology was 77% in HIV positive individuals as against 50% in HIV negative individuals [15].
In another report of a cervical cytology follow up of 409 HIV positive women, progression of
cervical lesions occurred in 39 cases. In 24 [61.5%) cases, the first diagnosis was benign cellular
changes (BCC) and 21 out of the 24 cases had low-grade squamous intraepithelial lesion (LSIL)
after one year. In 11 (28.2%) out of the 204 cases, the first diagnosis was BCC, and 9 cases had
high-grade intraepithelial lesion (HSIL) after I year. In 2 (5.0%) out of the 204 cases, the first
diagnosis was LSIL and the second was HSIL at one year interval. Two (5.0%) had the first
diagnosis as HSIL, and the second as invasive carcinoma at 2-yr interval [16]. Cervical
intraepithelial neoplasia (CIN) has also been reported to be more common in HIV positive
women with CD4 cell count < 200 cells /ul [17]. Cervical cancer has also been noted to occur in
younger women with HIV infection than in those without, and the peak incidence has been
reported to be a decade earlier [18]. These results point to the need for shorter screening
intervals for HIV positive women. In addition, the diagnosis of abnormal cervical cytology has
been shown to be unrelated with current intake of highly active anti-retroviral therapy
(HAART) [19]. It could therefore be beneficial to commence cervical cancer screening at an
earlier age possibly at age 19 years with a screening interval of 2 years for those with CD4
count ≥ 200 cells/ul and yearly for those with CD4 count < 200 cells/ul irrespective of HAART
status.
2.6. Pathophysiology of HIV infection
HIV infection lowers immunity through the destruction of CD4 lymphocytes. The first target
of HIV in the host system is the CD4 T cells. The HIV cell envelope binds to the CD4 cell
receptor causing further activation of co-receptors that will eventually lead to the fusion of
the host and viral cell membranes. The virus then gets totally into the host cell. This process
leads to the destruction of CD4 cells through various mechanisms as the virus multiplies
in the host system [20, 21].
The level of destruction is related to the level of HIV viral load in the patients system. CD4 cell
count and viral load are the recommended tests to measure HIV positive patients’ immune
status which can also indicate the rate of destruction of immune cells [22]. Progressive
reduction in CD4 cell population reduces the ability of the body to ward off infective agents
leading to occurrence of opportunistic infections in HIV infected individuals. Dormant
infections such as Herpes zoster can also be reactivated under conditions of depressed
immunity. These opportunistic infections add to the deterioration of the clinical states of HIV
infected patients leading to poor treatment outcome. Opportunistic infections are common if
CD4 cells count is below 200 cells/ul [23]. The list of common infections associated with
depressed immunity is presented in Table 3.
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Infective Agents Species
Viral Human Herpes viruses (Herpes simplex types 1 & 2, varicellazoster virus, Epstein-Barr virus,Cytomegalovirus), Measles, Respiratory syncytial virus, Influenza, Adenovirus
Bacterial Legionella pneumophila, Listeria monocytogenes, Salmonellatyphimurium, Mycobacterium tuberculosis, Atypical mycobacterium
Parasitic Pneumocystis pneumonia, Toxoplasma gondii, Cryptosporidia spp,
Fungal Candida spp, Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immiti
Table 3. Common opportunistic infections associated with depressed T cell immunity Adapted from Mackall (2000)
[23].
2.7. Clinical aspects of HIV infection and cervical cancer
The higher the HIV viral load, the more likely the compromise in the immune status. Cervical
cancer patients with HIV have been reported as having lower levels of CD4 cells count than
HIV sero positive patients without cervical cancer. In a report by Leitao and colleagues (2008)
comparing the CD4 cells count and viral load in 15 HIV positive cases with cervical cancer
with 60 HIV positive patients without cervical cancer controls, the median CD4 count for cases
was 208 cells/lL (range, 18-1102 cells/lL) while that for controls was 445 cells/lL (range, 20-1201
cells/lL) (p = 0.03). The median viral load was 16,918 copies/mL (range, 50-214,915 copies/mL)
for cases while that for control was 1430 copies/mL (range, 50-571,000 copies/mL) for controls
(p= 0.15 [24]). In the WHO staging of HIV, the association of HIV with cervical cancer is
classified under stage IV as with other AIDS defining malignancies indicating severity and
warrants the commencement of anti-retroviral therapy [25]. HIV infection is also noted to be
associated with high grade cervical cancer which leads to rapid progression of the disease.
2.8. Management of cervical cancer
The management of cervical cancer follows a multimodality approach. Relevant clinical
examinations and investigations to assess the stage of the disease and the suitability of the
patient for the modes of therapy have to be done. The choice of treatment depends on the stage
of the disease and the performance status of the patient. The treatment choice usually involves
surgery, radiotherapy and chemotherapy either alone or in combinations.
The treatment is usually chosen based on the stage of the disease. Treatment follows guidelines
that operate in various countries and regions. The European Society for Medical Oncology
(ESMO) guidelines (2012) is outlined in Table 4. [26]
2.9. CD4 cell count and cervical cancer treatment
Chemotherapy leads to suppressed immunity especially through the reduction of CD4 and
CD8 cell  counts  in  HIV positive  patients.  The effect  is  more marked on CD4 cells.  The
recovery is slow and better with CD8 than CD4 cells. The recovery of CD4 cells depends
on  the  state  of  the  thymus  gland  as  they  are  thymus  dependent.  The  thymus  gland
undergoes involution in the adults and hence recovery of CD4 cells count is usually very
slow in those with involute thymus gland. The effect of chemotherapy is more marked with
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alkylating agents, purine nucleoside analogues and steroids [23]. In a study to assess the
activity of the thymus gland after chemotherapy, it was reported that in younger patients
aged between 18-49  years,  the  thymus function  was  evident  in  63% of  the  participants
compared with 0% of their counterparts aged 70-91years three months post treatment [27].
Pelvic  radiotherapy  has  been  reported  to  lower  immune  cells  significantly  in  HIV sero
negative patients. These cells include CD4 T- lymphocytes, B cells and Helper T cells. The
reduction could be up to 50% in some instances [28, 29].
The advent of highly active anti-retroviral therapy (HAART) has improved the immunological
status of HIV positive patients and control the increase in viral load [30]. HAART leads to rapid
reduction in HIV viral load and sometimes to clinically undetectable level [31]. In a study to
assess the effects of combination chemotherapy on immune status of HIV associated lympho‐
ma patients, Powles (2002) reported that there was a significant drop in CD4 T cells. Following
completion of treatment, the recovery of CD4 T-cells was faster in patients receiving HAART
than in those without HAART [32]. The treatment with HAART does not however prevent the
development of cervical cancer in HIV positive patients [33].
Patients with compromised immunity usually suffer more treatment toxicities as well. Chemo-
radiotherapy used in the treatment of cervical cancer affect the immune status of patients.
Chemotherapy leads to immune cells suppression and the toxicity following radiotherapy is
increased in patients with compromised immunity [18]. HIV positive patients not on HAART
are therefore more likely to experience compromised immunity than those on HAART. With
decreasing immune status among HIV positive patients, the rate of decrease of CD4 cells can
be unpredictable and such patients can suffer from opportunistic infections that will further
complicate their conditions.
Stage Treatment Issue
IA1 Conization or simple hysterectomy ± salpingo-ophorectomy
and PLND if LVSI
Conservative surgery
IA2 Conization/radical trachelectomy or modified radical
hysterectomy and PLND
Adjuvant CT/RT if risk factors (LVSI, G3,
positive resection margins, multiple
nodes)
IB1, IIA Radical hysterectomy and PLND Adjuvant CT/RT if risk factors (LVSI, G3,
positive resection margins, multiple
nodes)
IB2, IIB–IV Combination CT/RT with cisplatin NACT to large bulky tumors prior to
CT/RT
PLND- pelvic lymphadenectomy; LVSI- lymphovascular space invasion; CT- computed
tomography; NACT- neoadjuvant chemotherapy; RT- radiation therapy
Table 4. Cervical cancer treatment according to Stage (ESMO guideline 2012).
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2.10. Management of cervical cancer in HIV positive patients
Decisions on the management of cervical cancer in HIV positive patients are not straight
forward. This is because of the immune concerns about such patients. Contributory factors to
immune compromise in such patients include the cancer, the HIV infection and the modalities
of treatment – chemotherapy and radiotherapy. There is the fear that oncology treatment will
worsen the immune status of treatment. Standard treatment as with HIV seronegative patients
are recommended. Radiation treatment of HIV positive patients with cervical cancer however,
has been reported to be associated with a seven fold increase in multi-systemic toxicities
compared with HIV sero-negative patients [18]. HIV patients with malignancy have also been
reported to have impaired ability of the mucosa to repair radiation damage. In treating
oropharyngeal tumour with radiation, it was reported that HIV positive patients had mucosal
reaction with lesser doses of radiation than HIV negative patients [34]. With regards to cervical
cancer, it is likely that the tissues with mucosal lining close to the treatment fields like urinary
bladder and gastro intestinal tract (GIT) might be affected in a similar way. This pattern of
mucosal reaction is attributable to low immune status of the patients.
Close to about 10% of HIV positive patients are also reported to be co-infected with hepatitis
B virus (HBV) or hepatitis C virus (HCV) or with both [35]. HIV positive patients diagnosed
with cervical cancer should therefore be routinely screened for HBV and HCV. A study in sub-
Sahara Africa reported that among HIV-infected individuals, mean HBV and HCV prevalence
rates were 15% and 7%, respectively [36]. Such co-infections have been reported to accelerate
the progression of HIV infection [37]. Such infections also warrant extra caution in using
HAART drugs that are metabolised in the liver to minimise liver toxicity that may occur [38].
Chemotherapy and radiotherapy may also activate viral hepatitis in such patients leading to
complications of therapy [39].
Essential measures to improve treatment tolerance and optimal outcome in HIV positive
patients with cervical cancer include early commencement of HAART (at diagnosis) based on
WHO recommendation of commencement of anti- retroviral therapy (ART) in WHO HIV stage
IV patients. Other studies have also recommended the commencement (at diagnosis) of ART
in all patients diagnosed with cancer based on the study results that show better outcome of
treatment in such patients. Such patients are noted to have better CD4 cell count and viral load
responses compared with those not on ART and are more likely to complete oncology
treatment on schedule [40, 41, 42]. Generally, early commencement of ART in HIV positive
individuals has been recently shown to be of benefit. In a randomized trial in Cote d’Ivore
West Africa, in which 2,056 participants with HIV-1 infection were included in the analysis
(Temprano Trial), it was reported that ART reduced the possibility of severe illness by 44% in
people starting treatment immediately at diagnosis, as compared to those starting ART only
when their CD4 levels drop to below 500/mm3. The study also reported that prophylaxis
against tuberculosis with isoniazid initiated among people living with HIV with a CD4 count
greater than 500/mm3 reduced the risk of severe illness by 35%, compared with those without
such treatment. Early initiation of isoniazid was also not associated with increase in the
development of resistance to isoniazid [43].
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Regular monitoring of CD4 cell count and viral load assay is needed towards early intervention
in case of derangements below critical levels. Msadabwe (2009) reported the CD4 cells count
trend during treatment and up to three months after treatment of HIV positive patients with
cervical cancer treated with chemoradiotherapy. The average initial CD4 cells count was 321.06
cells /mm2 at commencement of treatment. This gradually dropped to 62.56 cells/mm2 at the
end of treatment giving a mean difference of 258.2 cells /mm2. There was however, gradual
rise after treatment but by 3 months which was the end of the follow up period of the study,
the pre-treatment level was not reached. The average count at the end of three months was
one third of the pre-treatment value [44]. Significant drop in CD4 cells following radiotherapy
applies to both HIV negative and HIV positive patients especially if the radiation fields are
around areas with large lymphoid tissues such as the chest and pelvis. In HIV seronegative
patients treated for early stage breast cancer and stage I seminoma with radiotherapy, it was
reported that the CD4 cells count dropped by about 200 cells/ul and that pre-treatment levels
could not be attained after six years follow up [45]. Monthly CD4 cells count assay is therefore
needed to monitor the trend in CD4 cells count during treatment and at three monthly intervals
after treatment to ensure adequate CD4 count levels. This practice will enable the early
commencement of prophylaxis against opportunistic infections if CD4 cells count is below
critical levels so as to reduce morbidity in the patients. The recommended CD4 levels for
commencement of appropriate prophylaxis are presented in Table 5.
Pathogen Initiate Prophylaxis Preferred agent Discontinuation of Prophylaxis
Mycobacterium avium
complex (MAC)
CD4 <50 cells/mm3 Azithromycin 1200mg orally
once weekly or
Clarithromycin 500mg orally
twice weekly
CD4 count increase to >100
cells/mm3 for ≥3 months in
response to ART
Toxoplasma gondii
encephalitis (TE)
CD4 <100 cells/mm3 and
Positive serology for
Toxoplasma (IgG+)
Trimethoprim/
Sulfamethoxazole
(TMP/SMX) double strength
daily
Patient receiving ART with
increase in CD4 count to >200
cells/mm3 for ≥3 months
Pneumocystis pneumonia
(PCP)
CD4 <200 cells/mm3 or a
history of oropharyngeal
candidiasis
Trimethoprim/
Sulfamethoxazole
(TMP/SMX)
Single strength daily or double
strength three times weekly.
CD4 count >200 cells/mm3 for
>3 months in response to ART
⋅ Adequate viral suppression
⋅ If PCP occurred with CD4
>200 cells/mm3, prophylaxis
should be maintained
Table 5. Criteria for initiating and discontinuing prophylaxis for opportunistic infections in HIV positive patients
[adapted from NIH- AIDS Information 2015]. [46]
Other steps include testing for viral load every six months. This will ensure early diagnosis of
drug resistances as increasing viral load while patient is on ART may indicate onset of drug
resistance which should be promptly investigated and appropriate ART changes made.
External beam radiation therapy should be delivered at a daily dose of 1.8Gy per fraction to
HIV positive patients to minimize toxicity [47]. Patients with CD4 cells count less than 200
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cells/ul should be treated with 1.5Gy per fraction while the dose of weekly cisplatin should be
given at a reduced dose of 30-35mg/m2. These modifications have been reported to result in
treatment tolerance similar to HIV negative patients [45]. Patients with CD4 cells count less
than 150 cells /ul may however, not be able to withstand long course of radiation therapy and
should be given short course treatments depending on performance status. The rate of
completion of chemotherapy has been reported to be 30-45% among HIV positive patients
compared with 64-89% among HIV negative patients[48, 49].
The above measures could help in improving the rate of completion of treatment in HIV
positive patients. Renal dysfunction not myelo- suppression or gastrointestinal toxicity has
been reported in a retrospective study, to be the main cause of chemotherapy suspension in
HIV positive patients treated for cervical cancer and that chemotherapy was the most difficult
section to be completed in HIV positive patients [4]. Carboplatin chemotherapy may be
preferred to cisplatin in order to improve chemotherapy completion rate in HIV positive
patients. Patients with CD4 cells count less than 200 cells/ul should however, not receive
chemotherapy.
2.11. Drug interactions between chemotherapy and anti-retroviral agents
Platinum compounds commonly used in the chemotherapy of cervical cancer are cisplatin and
carboplatin. Patients with persistent or recurrent and metastatic disease can have paclitaxel
added to their treatment regimen [50]. On the other hand, anti-retroviral therapy in HIV
treatment consists of combinations of three different drugs from at least two different drug
classes (Table 6).
Nucleoside Reverse
Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse
Transcriptase Inhibitors
(NNRTIs)
Protease Inhibitors Entry and Integrase
Inhibitors
Abacavir (ABC) Delavirdine (DLV) Atazanavir (ATV) Dolutegravir (DTG)
Didanosine (ddI) *Efavirenz (EFV) Darunavir (DRV) Elvitegravir (EVG)
Emtricitabine (FTC) Etravirine (ETR) Fosamprenavir (FPV/
FOS-APV)
Maraviroc (MVC)
*Lamivudine [3TC) Nevirapine (NVP) Indinavir (IDV) Raltegravir (RAL)
*Stavudine (d4T) Rilpivirine (RPV) Lopinavir
*Tenofovir (DF/TDF) Nelfinavir (NFV)
Zidovudine AZT/ZDV Ritonavir (RTV)
Saquinavir (SQV)
Tipranavir (TPV)
*Drugs commonly used for first line treatment of HIV infections.
Table 6. Major HIV drug classes. At least three drugs from two drug classes are selected for the treatment of HIV when
ART is indicated Sources: NIH-NIAID, 2015; hiv-druginteractions.org 2015). [51]
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Commonly used first line drugs are stavudine or tenofovir, lamivudine [Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) and efavirenz [Non-Nucleoside Reverse Transcriptase
Inhibitors (NNRTIs) [4]. Various other second line combinations are used in cases of drug
resistance development or intolerable side effects of the first line combination drug regimen.
Pharmacokinetic enhancers like Cobicistat [COBI] can be included with some of the combina‐
tions to increase the effectiveness of the treatment. Most HIV positive patients diagnosed with
cervical cancer who are on HAART are likely to be placed on regimen containing the above
drugs [52, 53].
Possibilities of drug interactions and potentiation of toxicities exist among these chemotherapy
and ART drugs and these can affect treatment outcome. Paclitaxel is metabolized mainly by
CYP 2C8 enzyme of the cytochrome P450 system to 6 alpha-hydroxypaclitaxel. Paclitaxel
metabolites are inactive in comparison with the parent drug [54]. CYP 2C8 enzyme can be
inhibited by some ART drugs such as Delavirdine, Ritonavir, Fosamprenavir, Atazanavir,
Indinavir, Lopinavir, Nelfinavir and Saquinavir. Concomitant intake of any of these agents
can lead to increased toxicity of paclitaxel. On the other hand, Nevirapine is CYP 2C8 enzyme
inducer and on concomitant intake of this agent with paclitaxel can lead to accelerated
clearance of the active parent drug leading to ineffectiveness of paclitaxel [55].
Drugs Stavudine Tenofovir Lamivudine Efavirenz
Cisplatin a Potential interaction a Potential interaction b Potential interaction No interaction
Carboplatin c Potential interaction d Potential interaction e Potential interaction No interaction
Paclitaxel No interaction No interaction No interaction f Potential interaction
a Might increase risk of neuropathy as both drugs could cause neuropathy.
b Cisplatin is eliminated through renal route via organic cation transporter 2 (OCT2) and human multidrug and toxin
extrusion 1 (MATE1) enzymes. Cisplatin and lamivudine could compete for OCT2 which could slow their elimination.
Lamivudine dose could be adjusted.
c Carboplatin and stavudine administered together can increase the risk of peripheral neuropathy due to additive toxicity.
d. Both have nephrotoxic potential. Dose of tenofovir may need to be adjusted appropriately.
e. Lamivudine may affect renal function hence dose may need to be adjusted.
f Efavirenz is a strong inhibitor of CYP2C8 enzyme mostly involved in the metabolism of paclitaxel. Co administration
of these agents may increase the toxicity of paclitaxel.
NB. The above interactions are supported by very low levels of evidence.
Table 7. Cytotoxic and HIV drugs interactions relevant to HIV and cervical cancer (Source: HIV drugsinteraction.org.
Accessed 2015 March 11).
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There can be overlapping side effects between chemotherapy and ART drugs. Myelo-sup‐
pression is associated with most chemotherapeutic agents including paclitaxel and platinum
compounds and this can also be induced by the ART drug zidovudine. Paclitaxel can also cause
neuropathy likewise didanosine and stavudine. Care therefore has to be exercised in patients
that take these drugs concomitantly or other alternatives should be given. Cisplatin and
carboplatin can cause nephrotoxicity likewise the ART drug tenofovir while nausea and
vomiting which is common with most chemotherapy drugs can also be induced by ART drugs
in the classes of protease inhibitors, nucleoside and nonnucleoside reverse transcriptase
inhibitors [50]. Patients on these agents should have effective management of nausea and
vomiting with potent anti-emetics.
The possible interactions of cytotoxic drugs commonly used in cervical cancer chemotherapy
with first line drugs used in the treatment of HIV infection are presented in Table 7 above.
Interactions between cytotoxic drugs used in the treatment of cervical cancer and first line ART
drugs are quite favorable as contained in Table 7 with the associated levels of evidence.
Combining the treatment modalities in HIV positive patients should therefore be tolerated by
most patients.
3. Conclusion
The outcome of treatment in HIV positive patients diagnosed with cervical cancer is still poor
especially in regions with high prevalence of HIV and cervical cancer. This could be improved
through prompt commencement of such patients on ART at diagnosis. Close monitoring of
the immune status (CD4 cell) and viral load is needed to ensure early diagnosis of depressed
immune status and HAART treatment resistance. This could give early indication for com‐
mencement of appropriate prophylaxis against opportunistic infections and review of ART
drug combinations. There is need to continue further search for other modes of treatment such
as targeted therapies and radio sensitizers that can improve the effectiveness of managing HIV
positive patients diagnosed with cervical cancer. Prospective studies are also needed to
establish optimal radiation and chemotherapy doses in HIV positive patients diagnosed with
cervical cancer.
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